Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 3, 2007, Pages

  Kiley, Susan C ^a   Chevalier, Robert L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Activated Src; Apoptosis; Mouse proximal tubule cells; Tubule injury

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; STEROID RECEPTOR COACTIVATOR 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPECIES DIFFERENCE;

EID: 34548645387     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00227.2007     Document Type: Article

References (38)

1. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of nonsmall-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
2. Baker CH, Pino MS, Fidler IJ. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia 8: 470-476, 2006.
3. Bao J, Gur G, Yarden Y. Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci USA 100: 2438-2443, 2003.
4. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178, 2006.
5. Bellmunt J, Montagut C, Abiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99: 274-280, 2006.
6. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274: 8335-8343, 1999.
7. Boerner JL, Demory ML, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 24: 7059-7071, 2004.
8. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 44: 262-273, 2005.
9. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
10. Cachat F, Lange-Sperandio B, Chang AY, Kiley SC, Thornhill BA, Forbes MS, Chevalier RL. Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. Kidney Int 63: 564-575, 2002.
11. Cartier N, Lacave R, Vallet V, Hagege R, Hellio J, Robine S, Pringault E, Cluzeaud F, Briand P, Kahn A, Vandewalle A. Establishment of proximal tubule cell lines by targeted oncogenesis in transgenic mice using the L-pyruvate kinase-SV40 (T) antigen hybrid gene. J Cell Sci 104: 695-704, 1993.
12. Chevalier RL, Goyal S, Wolstenholme JT, Thornhill BA. Obstructive nephropathy in the neonatal rat is attenuated by epidermal growth factor. Kidney Int 54: 38-47, 1998.
13. Daly JM, Olayioye MA, Wong AML, Neve R, Lane HA, Maurer FG, Hynes NA. NDF/heregulin-induced cell cycle changes and apoptosis in breast cancer cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18: 3440-3451, 1999.
14. Emlet DR, Moscatello DK, Ludlow LB, Wong AJ. Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 272: 4079-4086, 1997.
15. Guillermo Paez J, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
16. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003.
17. Kennedy WA, Buttyan R, Garcia-Montes E, D'Agati V, Olsson CA, Sawczuk IS. Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction. Urology 49: 973-980, 1997.
18. Kiley SC, Thornhill BA, Tang SS, Ingelfinger JR, Chevalier RL. Growth factor-mediated phosphorylation of proapoptotic BAD reduces tubule cell death in vitro and in vivo. Kidney Int 63: 33-42, 2003.
19. Kiley SC, Thornhill BA, Belyea BC, Neale K, Forbes MS, Luetteke NC, Lee DC, Chevalier RL. Epidermal growth factor potentiates renal cell death in hydronephrotic neonatal mice, but cell survival in rats. Kidney Int 68: 504-514, 2005.
20. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 278: 1671-1679, 2003.
21. Kmiecik TE, Shalloway D. Activation and suppression of pp60c-Src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell 49: 65-73, 1987.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
23. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and hetrodimers. Mol Cell Biol 19: 6845-6857, 1999.
24. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12: 7242-7251, 2006.
25. Pinkas-Kramarski R, Lenferink AEG, Bacus SS, Lyass L, van de Poll MLM, Klapper LN, Sela M, van Zoelen EJJ, Yarden Y. The oncogenic ErbB2/ErbB3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene 16: 1249-1258, 1998.
26. Ram TG, Hosick HL, Ethier SP. Heregulin-β is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. J Cell Physiol 18: 301-313, 2000.
27. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner ED. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 101: 935-939, 1998.
28. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271: 27456-27461, 1996.
29. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57: 33-40, 2000.
30. Tang SS, Jung F, Diamant D, Brown D, Bachinsky D, Hellman P, Ingelfinger JR. Temperature-sensitive SV40 immortalized rat proximal tubule cell line has functional renin-angiotensin system. Am J Physiol Renal Fluid Electrolyte Physiol 268: F435-F446, 1995.
31. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, Friedlander G. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstital lesions after renal injury. J Clin Invest 106: 225-234, 2000.
32. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96: 1415-1420, 1999.
33. Tikhomirov O, Carpenter G. Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2. J Biol Chem 279: 12988-12996, 2004.
34. Torres VE, Sweeney WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 64: 1573-1579, 2003.
35. Torres VE, Sweeney WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int 66: 1766-1773, 2004.
36. Warren CM, Landgraf R. Signaling through ErbB receptors: multiple layers of diversity and control. Cell Signal 18: 923-933, 2006.
37. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA. Structure analysis of the lymphocyte-specific kinase Lck in complex with nonselective and Src family selective kinase inhibitors. Structure 7: 651-661, 1999.
38. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319: 991-997, 2006.